IMPAACT 2035

This is a Phase I/II, double-blinded, placebo-controlled, randomized multi-center study to assess the safety and immunogenicity of VPM1002 vaccination and BCG revaccination among South African pre-adolescents who received BCG vaccine at birth.

Rationale

VPM1002 vaccination and BCG revaccination will be safe when administered to pre-adolescents who received BCG vaccine at birth. VPM1002 vaccination and BCG revaccination will induce anti-mycobacterial cellular immune responses when administered to pre-adolescents who received BCG vaccine at birth.

Investigators

Prof Lee Fairlie (Principal Investigator)

Dr Faeezah Patel (Sub Investigator)

Dr Elizea Horne (Sub Investigator)

Latest Update

October 2023

For more about IMPAACT 2035 please email rhicomms@wrhi.ac.za